RESEARCH MONOGRAPH · KDC-MN-082

Semaglutide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

84/100

Genuinely important GLP-1 pharmacology with the cleanest weight-loss evidence base of any drug ever approved

Semaglutide is the real deal and we'll say it directly. The Novo Nordisk team (Lau, Knudsen, and colleagues) modified the GLP-1 backbone with an albumin-binding fatty acid side chain at position 26 plus residue substitutions that block DPP-4 cleavage, achieving a roughly week-long serum half-life. That pharmacokinetic engineering converted GLP-1 from a clinically impractical 2-minute-half-life endogenous peptide into a weekly subcutaneous medication that produces 15-17% mean body weight reduction in STEP and SELECT trials, plus a 20% cardiovascular event reduction in SELECT itself.

What we like is honestly almost everything. The mechanism is well-mapped: GLP-1R agonism in pancreatic beta-cells (insulin secretion), arcuate nucleus POMC/AgRP neurons (appetite suppression), gastric smooth muscle (delayed gastric emptying), and various extra-metabolic sites that are still being characterized. The clinical evidence base is the strongest of any weight-loss drug in history. SUSTAIN, STEP, SELECT, and now FLOW for kidney outcomes have all hit primary endpoints with effect sizes that obliterate the previous generation of weight loss pharmacology.

What we dont like is small but real. Nausea is the main tolerability issue and the dose escalation schedule is partly designed around it. The GI motility effects (delayed gastric emptying, occasional gastroparesis) are clinically meaningful in a subset of patients, and the long-half-life means GI symptoms persist longer than with shorter-acting GLP-1s. The thyroid C-cell carcinoma signal from rodent studies is probably not clinically translatable to humans (calcitonin biology differs) but the boxed warning isn't going away.

Sourcing is the messy part for research-use markets. Semaglutide is a 31-residue modified peptide with a complex fatty acid linker, making the synthesis non-trivial. Reputable peptide vendors can produce HPLC pure material at gram scale but cheap suppliers regularly underperform on the fatty acid attachment step. Mass spec verification is essential, not optional.

For studying GLP-1 receptor pharmacology, metabolic-axis modulation, or the next generation of nutrient-sensing-based therapeutics, semaglutide is the reference compound. This is genuinely one of the most important drugs of the decade and the underlying pharmacology is going to anchor weight metabolism research for the next 20 years.

Evidence: 95
Mechanism: 90
Reliability: 92
Safety: 80
Sourcing: 68
Value: 60
Signal: 92
Staying power: 92

Plain-language summary Intrigue 92 / 100

Semaglutide, sold as Ozempic and Wegovy, is the most prescribed GLP-1 receptor agonist. It improves blood sugar control and produces dramatic weight loss. The compound has a long half-life of about a week, supporting once-weekly injection. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

GLP-1 receptor agonist (long-acting)

A long-acting GLP-1 receptor agonist FDA-approved as Ozempic (T2DM) and Wegovy (obesity), with extended duration through albumin-binding and amino acid substitution.

Abstract

Semaglutide (Ozempic, Wegovy, Rybelsus; CAS 910463-68-2; molecular weight 4113.58) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk and approved for type 2 diabetes (Ozempic, 2017; Rybelsus oral, 2019) and chronic weight management (Wegovy, 2021). The compound is structurally based on native GLP-1 with two amino acid substitutions (Aib at position 8 to resist DPP-4 cleavage; Arg34Lys) and a fatty acid chain (octadecanoic diacid) attached via a glutamic acid spacer that enables reversible albumin binding for extended plasma half-life (approximately 1 week). Mechanism is GLP-1 receptor agonism producing glucose-dependent insulin release, glucagon suppression, gastric emptying delay, and central satiety effects. The semaglutide STEP program demonstrated 14 to 18 percent weight loss over 68 weeks in obesity trials; cardiovascular outcomes trials demonstrated MACE reduction in T2DM. Reported research dose ranges in the literature span roughly 1 mg weekly (Ozempic), 2.4 mg weekly (Wegovy), and 14 mg oral (Rybelsus). Schedule status: prescription-only.

Mechanism of action

GLP-1 receptor agonist with albumin-binding fatty acid extension for weekly dosing. Glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, satiety.

Reported research dose ranges

0.25 to 2.4 mg weekly (subcutaneous) or 3 to 14 mg oral (reported research dose ranges in the literature).

References

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-082

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Semaglutide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs